Monoclonal antibody program (Atengen)

N/A

Report date: 2022/07/26 10:28:56

Base Information

Drug NameMonoclonal antibody program (Atengen)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSolid tumoursMacular DegenerationDiabetic Retinopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAtengen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAtengen Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMacular DegenerationDiabetic Retinopathy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A